Update on intoxication by war neurotoxic agents: Pharmacological treatment (II);Actualización de las intoxicaciones por agentes neurotóxicos de guerra: Tratamiento farmacológico (II)

Atencion Farmaceutica

Volumn 4, Issue 3, 2002, Pages 178-188

  Pita Pita, R ^a   Anadon Navarro A ^a   Martinez Larranaga Ma R ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Atropine; Oximes; Scavengers; War neurotoxic agents

Indexed keywords

ANTICONVULSIVE AGENT; ATROPINE; BENZODIAZEPINE; CHEMICAL WARFARE AGENT; NEUROTOXIN; OBIDOXIME; OXIME; PRALIDOXIME; TRIMEDOXIME;

CHEMICAL WARFARE; DRUG STRUCTURE; HEALTH CARE PERSONNEL; HUMAN; INTOXICATION; NEUROTOXICITY; REVIEW; RISK ASSESSMENT; SPAIN; WAR;

EID: 17644449356     PISSN: 11397357     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. Bioscavengers as antidotes for organophosphorus (OP) agents
2. Organophosphate poisoning
3. The effects and treatment of nerve gas poisoning
4. Organophosphate poisoning
5. Secondary exposure of medical staff to sarin vapor in the emergency room
6. Sarin poisoning of a rescue team in the Matsumoto sarin incident in Japan
7. Unexpected nerve gas exposure in the city of Matsumoto: Report of rescue activity in the first sarin gas terrorism
8. The Tokyo subway sarin attack: Disaster management, part 2: Hospital response
9. Clinical features on nerve gas terrorism in Matsumoto
10. The sources, fate, and toxicity of chemical warfare agent degradation products
11. Treatment of organophosphorus poisoning: Pharmaceutical aspects of antidotes
12. Dimethylphosphoryl-inhibited human cholinesterases: Inhibition, reactivation, and aging kinetics
13. Clinical considerations in nerve agent intoxication
14. Nerve agents
15. The effect of a large dose of atropine upon the performance of routine tasks
16. Atropine poisoning in children during the Persian Gulf crisis: A national survey in Israel
17. The manifestations and treatment of poisoning due to nerve gas and other organic phosphate anticholinesterase compounds
18. Soman and sarin: Clinical manifestations and treatment of accidental poisoning by organophosphates
19. Sarin poisoning in Matsumoto, Japan
20. Progress in medical defense against nerve agents
21. Behavioral and electroencephalographic effects of atropine and related compounds
22. Sarin poisoning in Tokyo subway
23. Sarin poisoning in Tokyo subway
24. Organophosphorus nerve agents-induced seizures and efficacy of atropine sulfate as anticonvulsant treatment
25. Efficacy of biperiden and atropine as anticonvulsant treatment for organophosphorus nerve agent intoxication
26. Effects of atropine sulphate on seizure activity and brain damage produced by soman in guinea-pigs: ECoG correlates of neuropathology
27. Neuroprotective effects of currently used antidotes in soman-poisoned rats
28. The muscarinic antagonists aprophen and benactyzine are noncompetitive inhibitors of the nicotinic acetylcholine receptor
29. Actions and interactions of cholinolytics and cholinesterase reactivators in the treatment of acute organophosphorus toxicity
30. The influence of anticholinergic drug selection on the efficacy of antidotal treatment of soman-poisoned rats
31. Acetylcholinesterase. XI. Reversibility of tetraethyl pyrophosphate inhibition
32. Reappraisal of factors for the evaluation of oximes as reactivators of nerve agent-inhibited human acetylcholinesterase
33. The efficacy of bispyridinium derivatives in the treatment of organophosphonate poisoning in the guineapig
34. Reactivation of nerve agent inhibited human acetylcholinesterases by HI-6 and obidoxime
35. The bispyridinium-dioxime HLö-7: A potent reactivator for acetylcholinesterase inhibited by the stereoisomers of tabun and soman
36. Efficacy of HI-6 and HLö-7 in preventing incapacitation following nerve agent poisoning
37. Study on the stability of the oxime HI 6 in aqueous solution
38. Central activity of acetylcholinesterase oxime reactivators
39. Tabun, sarin, soman and VX poisoning in rats: Kinetics of inhibition of central and peripheral acetylcholinesterase, ageing, spontaneous and oxime-facilitated reactivation
40. Comparison of several oximes against poisoning by soman, tabun and GF
41. Reactivation by various oximes of human erythrocyte acetylcholinesterase inhibited by different organophosphorus compounds
42. Human toxicity of various oximes
43. Toxicology of oximes used in treatment of organophosphate poisoning
44. The reactivation by oximes of phosphonylated acetylcholinesterase: The possible erroneous interpretation of reactivating potency
45. Quantitative structure-activity relationships and possible mechanisms of action of bispyridinium oximes as antidotes against pinacolyl methylphosphonofluoridate
46. Acetylcholinesterase ractivators modify the functional properties of the nicotinic acetylcholine receptor ion channel
47. Effectiveness of oximes 2-PAM and HI-6 in recovery of muscle function depressed by organophosphate agents in the rat hemidiaphragm: An in vitro study
48. Efficacy of a combination of acetylcholinesterase reactivators, HI-6 and obidoxime, against tabun and soman poisoning of mice
49. Mechanism of oxime reactivation of acetylcholinesterase analyzed by chirality and mutagenesis
50. Analysis of cholinesterase inactivation and reactivation by systematic structural modification and enantiomeric selectivity
51. Effect of human plasma on the reactivation of sarin-inhibited human erythrocyte acetylcholinesterase
52. Role of edrophonium in prevention of the re-inhibition of acetylcholinesterase by phosphorylated oxime
53. Phosphoryl oxime inhibition of acetylcholinesterase during oxime reactivation is prevented by edrophonium
54. The phosphoryl oxime-destroying activity of human plasma
55. Stability study of a new antidote drug combination (atropine-HI-6-prodiazepam) for treatment of organophosphate poisoning
56. Call for diazepam replacement
57. Comparative evaluation of benzodiazepines for control of soman-induced seizures
58. Diazepam replacement
59. Anticonvulsant treatment of nerve agent seizures: Anticholinergics versus diazepam in soman-intoxicated guinea pigs
60. A study of the N-methyl-D-aspartate antagonistic properties of anticholinergic drugs
61. Dizocilpine (MK-801) arrests status epilepticus and prevents brain damage induced by soman
62. Nerve agent poisoning in primates: Antilethal, anti-epileptic and neuroprotective effects of GK-11
63. Acute soman poisoning in primates neither pretreated nor receiving immediate therapy: Value of gacyclidine (GK-11) in delayed medical support
64. Review of the value of gacyclidine (GK-11) as adjuvant medication to conventional treatments of organophosphate poisoning: Primate experiments mimicking various scenarios of military or terrorist attack by soman
65. Binding properties of [3H]gacyclidine in the rat central nervous system
66. Acetylcholinesterase prophylaxis against organophosphate poisoning: Quantitative correlation between protection and bloodenzyme level in mice
67. Butyrylcholinesterase and acetylcholinesterase prophylaxis against soman poisoning in mice
68. Comparison of antidote protection against soman by pyridostigmine, HI-6 and acetylcholinesterase
69. Protection by butyrylcholinesterase against organophosphorus poisoning in nonhuman primates
70. Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity: In vitro and in vivo quantitative characterization
71. Recombinant cholinesterases: Developing an ideal bioscavenger for protection against organophosphate nerve agents
72. Amplification of the effectiveness of acetylcholinesterase for detoxification of organophosphorus compounds by bis-quaternary oximes
73. Mutant acetylcholinesterases as potential detoxification agents for organophosphate poisoning
74. Improvements in scavenger protection against organophosphorus agents by modification of cholinesterases
75. Protein engineering of a human enzyme that hydrolyzes V and G nerve agents: Design, construction and characterization
76. Suxamethonium sensitivity
77. L'uso delle colinesterasi sieriche nella intossicazione grave da organofosforici: Nostra esperienza
78. Reversal of intense mivacurium block with human plasma cholinesterase in patients with atypical plasma cholinesterase
79. Succinylcholine-induced prolonged apnea in a 3-week-old newborn: Treatment with human plasma cholinesterase
80. Cocaine and butyrylcholinesterase (BChE): Determination of enzymatic parameters
81. Design and expression of organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase
82. Organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase: Synergy results in somanase
83. Role of oligosaccharides in the pharmacokinetics of tissue-derived and genetically engineered cholinesterases
84. Structure of glycan moieties responsible for the extended circulatory life time of fetal bovine serum acetylcholinesterase and equine serum butyrylcholinesterase
85. Tetramerization domain of human butyrylcholinesterase is at the C-terminus
86. Conserved aromatic residues of the C-terminus of human butyrylcholinesterase mediate the association of tetramers
87. Quaternary associations of acetylcholinesterase: The polyproline attachment domain of the collagen tail
88. Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase
89. Comparison of cholinesterases and carboxylesterase as bioscavengers for organophosphorus compounds
90. New approaches to medical protection against chemical warfare nerve agents
91. Toxicokinetics of (±)-VX in hairless guinea pigs and marmosets - In vitro metabolism of (±)-VX
92. Prophylaxis against organophosphate poisoning by an enzyme hydrolysing organophosphorus compounds in mice
93. Protection against tabun toxicity in mice by prophylaxis with an enzyme hydrolyzing organophosphate esters
94. Inactivation of organophosphorus nerve agents by the phosphotriesterase from Pseudomonas diminuta
95. A purified recombinant organophosphorus acid anhydrase protects mice against soman
96. Antagonism of paraoxon intoxication by recombinant phosphotriesterase encapsulated within sterically stabilized liposomes
97. Enzymes hydrolyzing organophosphates as potential catalytic scavengers against organophosphate poisoning
98. Long circulating liposomes encapsulating organophosphorus acid anhydrolase in diisopropylfluorophosphate antagonism
99. Nerve agent bioscavengers: Protection against high- and low-dose organophosphorus exposure
100. Kinetics of nerve agent hydrolysis by human OPAA hydrolase
101. Stereochemical preferences for chiral substrates by the bacterial phosphotriesterase
102. Evidence that several conserved histidine residues arc required for hydrolytic activity of human paraoxonase/arylesterase
103. Structural determinants of the substrate and stereochemical specificity of phosphotriesterase
104. Enhancement, relaxation, and reversal of the stereoselectivity for phosphotriesterase by rational evolution of active site residues
105. High resolution X-ray structures of different metal-substituted forms of phosphotriesterase from Pseudomonas diminuta
106. Human and rabbit paraoxonases: Purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification
107. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin
108. The Arg 192 isoform of paraoxonase with low sarin-hydrolyzing activity is dominant in the Japanese
109. Expression of paraoxonase isoform did not confer protection from acute sarin poisoning in the Tokyo subway terrorist attack
110. Association of low PONI type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans
111. Rational design of organophosphorus hydrolase for altered substrate specificities
112. Alteromonas prolidase for organophosphorus G-agent decontamination
113. Organophosphate skin decontamination using immobilized enzymes